JP2024537784A5 - - Google Patents
Info
- Publication number
- JP2024537784A5 JP2024537784A5 JP2024519423A JP2024519423A JP2024537784A5 JP 2024537784 A5 JP2024537784 A5 JP 2024537784A5 JP 2024519423 A JP2024519423 A JP 2024519423A JP 2024519423 A JP2024519423 A JP 2024519423A JP 2024537784 A5 JP2024537784 A5 JP 2024537784A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- alkyl
- salt
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21199982.6 | 2021-09-29 | ||
| EP21199982 | 2021-09-29 | ||
| PCT/EP2022/076850 WO2023052363A1 (en) | 2021-09-29 | 2022-09-27 | Novel tetrahydroquinolines and proteolysis targeting chimera (protacs) comprising them as degraders of smarca |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024537784A JP2024537784A (ja) | 2024-10-16 |
| JP2024537784A5 true JP2024537784A5 (enExample) | 2025-10-06 |
Family
ID=78211839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024519423A Pending JP2024537784A (ja) | 2021-09-29 | 2022-09-27 | 新規テトラヒドロキノリン及びｓｍａｒｃａの分解誘導物質としてそれらを含むタンパク質分解誘導キメラ（ｐｒｏｔａｃ） |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250049929A1 (enExample) |
| EP (1) | EP4408846A1 (enExample) |
| JP (1) | JP2024537784A (enExample) |
| CN (1) | CN118019741A (enExample) |
| WO (1) | WO2023052363A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202409036A (zh) * | 2022-05-17 | 2024-03-01 | 美商858療法股份有限公司 | Parg抑制劑 |
| CN119403803A (zh) | 2022-05-17 | 2025-02-07 | 858治疗公司 | Parg抑制剂 |
| EP4695250A1 (en) | 2023-04-12 | 2026-02-18 | Aurigene Oncology Limited | Tetracyclic compounds as smarca2 and/or smarca4 degraders |
| WO2025106482A1 (en) * | 2023-11-13 | 2025-05-22 | Oncopia Therapeutics, Inc. D/B/A Sk Life Science Labs | Compounds and compositions as smarca2/4 degraders and uses thereof |
| AR134429A1 (es) * | 2023-11-22 | 2026-01-14 | 858 Therapeutics Inc | Inhibidores de parg |
| CN119330886B (zh) * | 2024-09-03 | 2026-03-20 | 常州大学 | 一种苯并咪唑胺类衍生物及其制备方法和作为β2-肾上腺素受体别构拮抗剂的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41598A (fr) | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| CN112996800B (zh) | 2018-10-16 | 2024-06-25 | 勃林格殷格翰国际有限公司 | 作为smarca2和/或smarca4的降解剂的新型蛋白水解靶向嵌合体（protac）及其衍生物 |
| KR20210097733A (ko) * | 2018-11-30 | 2021-08-09 | 메르크 파텐트 게엠베하 | 전자 디바이스용 화합물 |
| WO2020251969A1 (en) * | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
-
2022
- 2022-09-27 WO PCT/EP2022/076850 patent/WO2023052363A1/en not_active Ceased
- 2022-09-27 EP EP22798245.1A patent/EP4408846A1/en active Pending
- 2022-09-27 US US18/695,941 patent/US20250049929A1/en active Pending
- 2022-09-27 CN CN202280065436.1A patent/CN118019741A/zh active Pending
- 2022-09-27 JP JP2024519423A patent/JP2024537784A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024537784A5 (enExample) | ||
| JP2022539089A5 (enExample) | ||
| JP2024504932A5 (enExample) | ||
| HRP20151425T1 (hr) | Inhibitori indazola wnt signalnog puta i njihove terapeutske uporabe | |
| BRPI0212894B1 (pt) | Composto ou sal do mesmo farmaceuticamente aceitável e composição farmacêutica | |
| JP2022108241A5 (enExample) | ||
| RU2012146986A (ru) | Цефемовые соединения, содержащие катехольную группу | |
| JP2018524339A5 (enExample) | ||
| RU2002101723A (ru) | Инданилзамещенные бензолкарбонамиды, способ их получения, их применение в качестве лекарственного средства, а также содержащие их фармацевтические композиции | |
| ES2694685T3 (es) | Profármacos solubles en agua cargados positivamente de ácidos n-arilantranílicos con muy rápida velocidad de penetración en la piel | |
| RU2012110246A (ru) | Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора | |
| JP2013502431A5 (enExample) | ||
| RU2015119999A (ru) | Пиримидиновые нуклеозиды и их монофосфатные пролекарства для лечения вырусных инфекций и рака | |
| KR960703580A (ko) | 눈의 염증성 질환을 치료하기 위한 3-벤조일페닐아세트산 유도체를 함유하는 국소투여가능한 조성물(Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders) | |
| RU2000131183A (ru) | Производные оксииминоалкановой кислоты | |
| RU2014113539A (ru) | Тетрациклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний | |
| BRPI0817864A2 (pt) | uso de um composto derivado de ceramida | |
| JP2023518777A5 (enExample) | ||
| AU2003228593B2 (en) | Pharmaceutical composition comprising an alpha-ketoalkanoic acid ester or -amine and lactic acid or a lactic acid salt | |
| RU99127433A (ru) | Эрголиновые производные и их применение в качестве антагонистов рецепторов соматостатина | |
| RU2001121650A (ru) | Композиции для лечения кожных заболеваний | |
| JP2022510587A5 (enExample) | ||
| RU2005133665A (ru) | Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств | |
| JP2010505869A5 (enExample) | ||
| WO2008113557A2 (en) | Anti-infective agents |